Drug Shortage Report for APO-RIVASTIGMINE

Last updated on 2019-10-15 History
Report ID 20900
Drug Identification Number 02336715
Brand name APO-RIVASTIGMINE
Common or Proper name RIVASTIGMINE
Company Name APOTEX INC
Market Status MARKETED
Active Ingredient(s) RIVASTIGMINE
Strength(s) 1.5MG
Dosage form(s) CAPSULE
Route of administration ORAL
Packaging size 100 BTL
ATC code N06DA
ATC description ANTI-DEMENTIA DRUGS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2017-10-20
Actual start date 2017-10-16
Estimated end date 2019-10-18
Actual end date 2019-10-11
Shortage status Resolved
Updated date 2019-10-15
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 150 SIGNET DRIVE
TORONTO, ONTARIO
CANADA M9L 1T9
Company contact information Apotex Customer Service - 1-877-427-6839

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v38 2019-10-15 French Compare
v37 2019-10-15 English Compare
v36 2019-09-20 French Compare
v35 2019-09-20 English Compare
v34 2019-07-30 French Compare
v33 2019-07-30 English Compare
v32 2019-07-30 French Compare
v31 2019-07-30 English Compare
v30 2019-06-25 French Compare
v29 2019-06-25 English Compare
v28 2019-05-06 French Compare
v27 2019-05-06 English Compare
v26 2019-03-27 French Compare
v25 2019-03-27 English Compare
v24 2018-10-19 French Compare
v23 2018-10-19 English Compare
v22 2018-10-11 French Compare
v21 2018-10-11 English Compare
v20 2018-08-20 French Compare
v19 2018-08-20 English Compare

Showing 1 to 20 of 38